Ixchiq (VLA1553 / Chikungunya live-attenuated vaccine)

Approved / Licensed

Developer: Valneva  |  Target Disease: Chikungunya

  1. Phase 1
  2. Phase 2
  3. Phase 3
  4. Filed
  5. Approved
Development Phase Approved / Licensed Primary Status
Platform Technology Live attenuated Biologic Architecture
Target Indication Chikungunya Pathogen / Antigen
Last Verified 2026-08-01 Tier 1 Multi-Source Checked

Multi-Jurisdiction Regulatory Status

Official licensing, rolling submissions, or authorization status tracked across major health authorities.

Regulatory Authority Status & Details
US FDA Approved / Authorized Date: 2023-11-09FDA accelerated approval for individuals 18+ at high risk of chikungunya virus exposure
EMA (Europe) Approved / Authorized Date: 2024-06-28EMA approved for active immunization of individuals 18+
Health Canada Approved / Authorized Date: 2024-06-14Health Canada approved
TGA (Australia) Under Regulatory Review Date: 2024-09-01TGA submission under evaluation

Progress and adoption outlook

Where this candidate sits on a fixed development ladder, and when a licence and a routine-use recommendation could follow in each jurisdiction, as scenario bands. Input grade: Regulator-confirmed status date in at least one jurisdiction.

90% of the ladderA · regulator-dated
  1. Preclinical
  2. Phase 1
  3. Phase 1/2
  4. Phase 2
  5. Phase 2/3
  6. Phase 3
  7. Submitted to a regulator
  8. Under regulatory review
  9. Approved / authorised
  10. Recommended for routine use

Current position: Approved / authorised

Status and projected windows by jurisdiction
JurisdictionStatus in the recordSubmissionRegulator decisionEarliest routine use
United StatesFDA (CBER) · ACIP (CDC)approved (2023-11-09, regulator confirmed)—2023-112023-11 to 2023-11—
European UnionEMA (CHMP) and European Commission · national bodies (STIKO, HAS, Folkhälsomyndigheten and others)approved (2024-06-28, regulator confirmed)—2024-062024-06 to 2024-06—
CanadaHealth Canada · NACIapproved (2024-06-14, regulator confirmed)—2024-062024-06 to 2024-06—
United KingdomMHRA · JCVIno jurisdiction-specific filing knownThe MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used.
AustraliaTGA · ATAGIunder review (2024-09-01, company estimate)TGA registration-timeframe pages timed out on 2026-10-24; no target is used.
JapanPMDA / MHLW · MHLW immunisation subcommitteeno jurisdiction-specific filing knownPMDA English pages reached on 2026-10-24 state that target review times exist but give no figure.
WHO prequalificationWHO Prequalification · SAGEno jurisdiction-specific filing knownWHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used.

Each window shows the typical scenario with the fast-to-slow band beneath it (year-month). Bands come from the parameters on the outlook model page; they are not forecasts.

Scientific Profile & Documentation

Platform Architecture
Live attenuated
Lead Developer
Valneva
Next Expected Milestone
Post-marketing safety surveillance; adolescent trial data readout
Analyst & Development Notes
Required edge case: approval is not always terminal. A licensed vaccine can be suspended or restricted post-approval. Re-verify live FDA/EMA status before publishing clinical implications.

Registered Clinical Trials & Studies

Direct registry links to active, completed, or pivotal registration studies across phases.

No primary ClinicalTrials.gov record linked directly. Study data tracked via regulatory submission filings and peer-reviewed releases.

Milestone Overview

  • Stage Verification
    Approved / Licensed confirmed as of 2026-08-01.
  • Target Milestone
    Post-marketing safety surveillance; adolescent trial data readout

Vaccine Data Navigator Candidate Profile Registry:

This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.